Monograph Details
|
|
Gastrointestinal Tract
> Colorectal disorders
|
|
LIALDA |
| Manufacturer |
|
Shire US, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Aminosalicylate. |
| Generic Name |
|
Mesalamine 1.2g; del-rel tabs. |
| Indications |
|
To induce remission in active, mild-to-moderate ulcerative colitis. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: Swallow whole with a meal. 2.4–4.8g once daily for up to 8 weeks. |
| Precautions |
|
Sulfasalazine allergy. Pyloric stenosis. Conditions predisposing to myocarditis or pericarditis. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Increased toxicity with nephrotoxic drugs (eg, NSAIDs), 6-mercaptopurine, azathioprine. |
| Adverse Reactions |
|
Headache, flatulence; acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea, fever, headache, rash) (discontinue if suspected), renal impairment, cardiac hypersensitivity reactions, pancreatitis (rare). |
| How Supplied |
|
Tabs—120 |
|
|
|
|
